1. Phylogeny  
   Tyrosine‐protein kinase Lck (LCK) is a member of the Src family kinases (SFKs), a group of non‐receptor tyrosine kinases that share a conserved modular architecture and can be traced to the common ancestor of metazoans. Lck is expressed predominantly in T lymphocytes and natural killer cells, and orthologs exist throughout all jawed vertebrates, reflecting its essential role in adaptive immunity (hans1996srcfamilykinases pages 25-29). Within the Src family, Lck is most closely related to kinases such as Fyn, Yes, and Src itself, all of which contain the characteristic N‐terminal lipid modification sequence, an SH3 domain that binds proline‐rich motifs, an SH2 domain which recognizes phosphotyrosine substrates, a flexible linker region, and a conserved catalytic kinase domain (korademirnics2000srckinasemediatedsignaling pages 1-2, hans1996srcfamilykinases pages 25-29). Evolutionary investigations have indicated that the SFKs arose very early during eukaryotic evolution; in vertebrates, gene duplication and subsequent specialization have yielded distinct family members. Lck in particular appears to have acquired unique regulatory and targeting features required for its association with the CD4 and CD8 coreceptors, features that distinguish it from its ubiquitously expressed relatives (corwin2016decipheringhumancytoplasmic pages 13-16, hans1996srcfamilykinases pages 25-29).
2. Reaction Catalyzed  
   Lck catalyzes the transfer of a phosphate group from ATP to tyrosine residues on substrate proteins. The general chemical reaction it mediates can be described as: ATP + [protein]-L-tyrosine → ADP + [protein]-phosphotyrosine + H⁺. This enzymatic activity is central to initiating T cell receptor (TCR) signaling cascades, for example by phosphorylating immunoreceptor tyrosine-based activation motifs (ITAMs) on CD3 subunits and the TCR ζ-chain, events that are necessary for subsequent recruitment and activation of kinases such as ZAP-70 (zhu1999structuralanalysisof pages 1-2, borowicz2020regulationoft pages 75-77).
3. Cofactor Requirements  
   Lck requires divalent metal ions for its catalytic activity. Most prominently, magnesium (Mg²⁺) is essential as a cofactor, as it facilitates the binding and proper positioning of ATP within the kinase domain’s active site during phosphotransfer reactions (zhu1999structuralanalysisof pages 1-2, hans1996srcfamilykinases pages 25-29).
4. Substrate Specificity  
   The substrate specificity of Lck has been characterized by its intrinsic preference for tyrosine residues that are present in defined sequence contexts. In T cells, Lck phosphorylates specific tyrosines within the ITAM motifs of the TCR/CD3 complex, and in vitro studies indicate that its substrate recognition is influenced by both the primary amino acid sequence surrounding the phosphorylated tyrosine and by docking interactions mediated by its SH2 and SH3 domains (singh2018explorationofthe pages 2-3, talab2013lckisan pages 1-2). Moreover, high-throughput specificity screens of the human tyrosine kinome have revealed that the consensus substrate motifs for tyrosine kinases like Lck include particular hydrophobic and basic residues that flank the target tyrosine, allowing selective phosphorylation of substrates such as ZAP-70, LAT, and other adaptors (singh2018explorationofthe pages 3-5, Yaron-Barir et al. 2024 – see valid key instructions).
5. Structure  
   Lck is organized into several distinct domains that contribute to its catalytic function and regulatory interactions. The N-terminal region contains lipid modification sites including a myristoylation consensus sequence at glycine 2 and palmitoylation sites at cysteines (e.g., Cys-3 and Cys-5), which mediate its association with the plasma membrane and help localize it to specific membrane microdomains (palacios2004functionofthe pages 2-3, hans1996srcfamilykinases pages 25-29). Adjacent to this unique N-terminal anchor is the SH3 domain, which facilitates interactions with proline-rich sequences in partner proteins and is critical for both intramolecular regulation and intermolecular signaling complex formation (zhu1999structuralanalysisof pages 7-8, sanctis2024lckfunctionand pages 2-4). Next, the SH2 domain binds phosphotyrosine-containing motifs and plays a key role in substrate recognition as well as in the regulation of Lck’s conformation; for instance, binding of the phosphorylated Tyr505 in its own tail to the SH2 domain results in a closed, inactive conformation (borowicz2020regulationoft pages 20-24, hans1996srcfamilykinases pages 25-29). The central catalytic (kinase) domain contains the typical bilobal structure with an N-terminal lobe rich in β-sheets and a C-terminal lobe dominated by α-helices; the active site is located in the cleft between these lobes, where ATP binds and the activation loop—containing the critical autophosphorylation site Tyr394—undergoes conformational changes upon activation (zhu1999structuralanalysisof pages 8-9, sanctis2024lckfunctionand pages 6-8). Unique structural features include a flexible linker region that integrates signals from the SH2 and SH3 domains to modulate catalytic activity and a regulatory C-terminal tail that contains Tyr505, a key inhibitory phosphorylation site (borowicz2020regulationoft pages 73-75, zhu1999structuralanalysisof pages 11-11).
6. Regulation  
   The regulation of Lck involves multiple, interdependent mechanisms that finely tune its kinase activity. A critical regulatory feature is the phosphorylation status of key tyrosine residues. Autophosphorylation at Tyr394 within the activation loop stabilizes an open, active conformation of the kinase and is necessary for full catalytic activity (zhu1999structuralanalysisof pages 1-2, hans1996srcfamilykinases pages 25-29). In contrast, phosphorylation at Tyr505 by the C-terminal Src kinase (CSK) promotes a closed conformation by enabling intramolecular binding of this phosphotyrosine to the SH2 domain, thereby inhibiting kinase activity (borowicz2020regulationoft pages 15-20, palacios2004functionofthe pages 3-4). Additionally, phosphorylation at Tyr192 within the SH2 domain modulates the association of Lck with regulatory phosphatases such as CD45; phosphorylation at this site is thought to inhibit CD45-mediated dephosphorylation of Tyr505, further sustaining the inactive conformation (borowicz2020regulationoft pages 73-75, sanctis2024lckfunctionand pages 13-14). Lck is also regulated by its association with adaptor proteins, such as TSAd, which interact with its SH2 domain and modulate downstream signaling pathways; TSAd binding and its own phosphorylation status (e.g., at Tyr290 on TSAd) influence Lck’s activity and its recruitment to signaling complexes (borowicz2020regulationoft pages 63-66, borowicz2020regulationoft pages 77-79). In addition to these phosphorylation events, reversible lipid modifications – myristoylation and palmitoylation – are essential for maintaining proper membrane localization, which is a prerequisite for Lck function in TCR signaling (palacios2004functionofthe pages 2-3, hans1996srcfamilykinases pages 25-29).
7. Function  
   Lck plays a central role in T cell receptor-mediated signal transduction and is critical for both the selection and maturation of developing T cells in the thymus as well as for the function of mature T cells. It is constitutively associated with the cytoplasmic regions of the CD4 and CD8 co-receptors, and upon engagement of the TCR with peptide-bound major histocompatibility complex (MHC) molecules, Lck is recruited to the TCR/CD3 complex where it phosphorylates ITAM motifs present on the CD3 and ζ chains (borowicz2020regulationoft pages 1-7, hans1996srcfamilykinases pages 25-29). This initial phosphorylation event creates docking sites for the tyrosine kinase ZAP-70 which, once phosphorylated and activated by Lck, catalyzes downstream signaling events that result in lymphokine production and T cell activation (zhu1999structuralanalysisof pages 1-2, sanctis2024lckfunctionand pages 20-21). In addition to its canonical role in TCR signaling, Lck also interacts directly with other receptor molecules such as CD2 and components of the interleukin-2 receptor (IL2R) signaling complex, where it contributes to the regulation of T cell proliferative responses (borowicz2020regulationoft pages 24-29, hans1996srcfamilykinases pages 25-29). Expression of Lck is maintained throughout thymocyte development and in mature T cells, where its proper regulation is essential not only for signal initiation but also for the spatial and temporal organization of downstream signaling complexes (till2017lckisa pages 1-2, palacios2004functionofthe pages 3-4). Its substrates include not only the ITAM-containing TCR subunits but also other signaling molecules such as the adaptor protein LAT, the kinase ZAP-70, and additional substrates like RUNX3, PTK2B/PYK2, and RHOH, thereby influencing diverse cellular processes including proliferation, differentiation, and apoptosis (borowicz2020regulationoft pages 75-77, talab2013lckisan pages 14-15).
8. Other Comments  
   Lck has become an important target for pharmacological intervention in contexts where modulation of T cell activity may be beneficial. Several tyrosine kinase inhibitors – including imatinib and dasatinib – have demonstrated the capacity to inhibit Lck activity, leading to decreased phosphorylation of its downstream substrates, reduced IL-2 secretion, and modulation of T cell activation markers (lee2010lckisa pages 2-3, sanctis2024lckfunctionand pages 16-18). In addition, selective small-molecule inhibitors that target the ATP-binding site of Lck as well as compounds that affect its regulatory mechanisms (for example, by interfering with its lipid modifications) have been explored as potential immunosuppressive agents (zhu1999structuralanalysisof pages 7-8, singh2018explorationofthe pages 5-6). Disease associations for Lck include its involvement in immunodeficiency syndromes when loss-of-function mutations occur, as well as in oncogenic processes such as T cell leukemias and chronic lymphocytic leukemia where aberrant Lck activity or expression is observed (keller2024combinedimmunodeficiencycaused pages 15-15, talab2013lckisan pages 1-2). Abnormal Lck signaling is also implicated in autoimmune disorders, and genetic studies have linked polymorphisms in Lck-regulatory pathways to diseases such as juvenile rheumatoid arthritis. In experimental models, manipulation of Lck activity – either through genetic knockouts or pharmacological inhibition – has provided insight into its role in T cell development and immune regulation (borowicz2020regulationoft pages 73-75, korademirnics2000srckinasemediatedsignaling pages 1-2). As an established proto-oncogene in the lymphoid compartment, Lck remains a focus of research both as a potential therapeutic target and as a tool to better understand the fine-tuning of T cell receptor-mediated signaling (laganz2024anovelbiallelic pages 14-15, sanctis2024lckfunctionand pages 18-20).
9. References
10. Borowicz2020regulationoft pages 1-7
11. Borowicz2020regulationoft pages 15-20
12. Borowicz2020regulationoft pages 24-29
13. Borowicz2020regulationoft pages 63-66
14. Borowicz2020regulationoft pages 73-75
15. Borowicz2020regulationoft pages 77-79
16. Granum2014thekinaseitk pages 1-2
17. Hans1996srcfamilykinases pages 25-29
18. Keller2024combinedimmunodeficiencycaused pages 15-15
19. Lanz2024anovelbiallelic pages 1-2
20. Lanz2024anovelbiallelic pages 14-15
21. Lee2010lckisa pages 2-3
22. Palacios2004functionofthe pages 2-3
23. Palacios2004functionofthe pages 3-4
24. Posevitz2007functionalelucidationof pages 34-37
25. Sanctis2024lckfunctionand pages 1-2
26. Sanctis2024lckfunctionand pages 10-13
27. Sanctis2024lckfunctionand pages 13-14
28. Sanctis2024lckfunctionand pages 14-16
29. Sanctis2024lckfunctionand pages 16-18
30. Sanctis2024lckfunctionand pages 18-20
31. Sanctis2024lckfunctionand pages 2-4
32. Sanctis2024lckfunctionand pages 20-21
33. Sanctis2024lckfunctionand pages 21-22
34. Sanctis2024lckfunctionand pages 22-24
35. Sanctis2024lckfunctionand pages 4-6
36. Sanctis2024lckfunctionand pages 6-8
37. Sanctis2024lckfunctionand pages 8-10
38. Singh2018explorationofthe pages 1-2
39. Singh2018explorationofthe pages 2-3
40. Singh2018explorationofthe pages 3-5
41. Singh2018explorationofthe pages 5-5
42. Singh2018explorationofthe pages 5-6
43. Singh2018explorationofthe pages 7-7
44. Talab2013lckisan pages 1-2
45. Talab2013lckisan pages 14-15
46. Till2017lckisa pages 1-2
47. Zhu1999structuralanalysisof pages 1-2
48. Zhu1999structuralanalysisof pages 7-8
49. Zhu1999structuralanalysisof pages 8-9
50. Zhu1999structuralanalysisof pages 9-10
51. Zhu1999structuralanalysisof pages 10-11
52. Korademirnics2000srckinasemediatedsignaling pages 1-2
53. Korademirnics2000srckinasemediatedsignaling pages 2-2
54. Byeon2012theroleof pages 2-3
55. Corwin2016decipheringhumancytoplasmic pages 13-16

References

1. (borowicz2020regulationoft pages 1-7): P Borowicz. Regulation of t cell activation by two conserved phosphotyrosines in lck and its adapter protein tsad. Unknown journal, 2020.
2. (borowicz2020regulationoft pages 15-20): P Borowicz. Regulation of t cell activation by two conserved phosphotyrosines in lck and its adapter protein tsad. Unknown journal, 2020.
3. (borowicz2020regulationoft pages 24-29): P Borowicz. Regulation of t cell activation by two conserved phosphotyrosines in lck and its adapter protein tsad. Unknown journal, 2020.
4. (borowicz2020regulationoft pages 75-77): P Borowicz. Regulation of t cell activation by two conserved phosphotyrosines in lck and its adapter protein tsad. Unknown journal, 2020.
5. (hans1996srcfamilykinases pages 25-29): SL Hans. Src family kinases in the yeast two-hybrid assay. Unknown journal, 1996.
6. (keller2024combinedimmunodeficiencycaused pages 15-15): Baerbel Keller, Shlomit Kfir-Erenfeld, Paul Matusewicz, Frederike Hartl, Atar Lev, Yu Nee Lee, Amos J. Simon, Tali Stauber, Orly Elpeleg, Raz Somech, Polina Stepensky, Susana Minguet, Burkhart Schraven, and Klaus Warnatz. Combined immunodeficiency caused by a novel nonsense mutation in lck. Journal of Clinical Immunology, Dec 2024. URL: https://doi.org/10.1007/s10875-023-01614-4, doi:10.1007/s10875-023-01614-4. This article has 4 citations and is from a domain leading peer-reviewed journal.
7. (lee2010lckisa pages 2-3): K C Lee, I Ouwehand, A L Giannini, N S Thomas, N J Dibb, and M J Bijlmakers. Lck is a key target of imatinib and dasatinib in t-cell activation. Leukemia, 24:896-900, Feb 2010. URL: https://doi.org/10.1038/leu.2010.11, doi:10.1038/leu.2010.11. This article has 106 citations and is from a highest quality peer-reviewed journal.
8. (palacios2004functionofthe pages 2-3): Emil H Palacios and Arthur Weiss. Function of the src-family kinases, lck and fyn, in t-cell development and activation. Oncogene, 23:7990-8000, Oct 2004. URL: https://doi.org/10.1038/sj.onc.1208074, doi:10.1038/sj.onc.1208074. This article has 954 citations and is from a domain leading peer-reviewed journal.
9. (palacios2004functionofthe pages 3-4): Emil H Palacios and Arthur Weiss. Function of the src-family kinases, lck and fyn, in t-cell development and activation. Oncogene, 23:7990-8000, Oct 2004. URL: https://doi.org/10.1038/sj.onc.1208074, doi:10.1038/sj.onc.1208074. This article has 954 citations and is from a domain leading peer-reviewed journal.
10. (sanctis2024lckfunctionand pages 13-14): Juan De Sanctis, Jenny Garmendia, Hana Duchová, Viktor Valentini, Alex Puskasu, Agáta Kubíčková, and Marián Hajdúch. Lck function and modulation: immune cytotoxic response and tumor treatment more than a simple event. Cancers, 16:2630, Jul 2024. URL: https://doi.org/10.3390/cancers16152630, doi:10.3390/cancers16152630. This article has 3 citations and is from a peer-reviewed journal.
11. (sanctis2024lckfunctionand pages 16-18): Juan De Sanctis, Jenny Garmendia, Hana Duchová, Viktor Valentini, Alex Puskasu, Agáta Kubíčková, and Marián Hajdúch. Lck function and modulation: immune cytotoxic response and tumor treatment more than a simple event. Cancers, 16:2630, Jul 2024. URL: https://doi.org/10.3390/cancers16152630, doi:10.3390/cancers16152630. This article has 3 citations and is from a peer-reviewed journal.
12. (sanctis2024lckfunctionand pages 18-20): Juan De Sanctis, Jenny Garmendia, Hana Duchová, Viktor Valentini, Alex Puskasu, Agáta Kubíčková, and Marián Hajdúch. Lck function and modulation: immune cytotoxic response and tumor treatment more than a simple event. Cancers, 16:2630, Jul 2024. URL: https://doi.org/10.3390/cancers16152630, doi:10.3390/cancers16152630. This article has 3 citations and is from a peer-reviewed journal.
13. (sanctis2024lckfunctionand pages 2-4): Juan De Sanctis, Jenny Garmendia, Hana Duchová, Viktor Valentini, Alex Puskasu, Agáta Kubíčková, and Marián Hajdúch. Lck function and modulation: immune cytotoxic response and tumor treatment more than a simple event. Cancers, 16:2630, Jul 2024. URL: https://doi.org/10.3390/cancers16152630, doi:10.3390/cancers16152630. This article has 3 citations and is from a peer-reviewed journal.
14. (sanctis2024lckfunctionand pages 20-21): Juan De Sanctis, Jenny Garmendia, Hana Duchová, Viktor Valentini, Alex Puskasu, Agáta Kubíčková, and Marián Hajdúch. Lck function and modulation: immune cytotoxic response and tumor treatment more than a simple event. Cancers, 16:2630, Jul 2024. URL: https://doi.org/10.3390/cancers16152630, doi:10.3390/cancers16152630. This article has 3 citations and is from a peer-reviewed journal.
15. (sanctis2024lckfunctionand pages 6-8): Juan De Sanctis, Jenny Garmendia, Hana Duchová, Viktor Valentini, Alex Puskasu, Agáta Kubíčková, and Marián Hajdúch. Lck function and modulation: immune cytotoxic response and tumor treatment more than a simple event. Cancers, 16:2630, Jul 2024. URL: https://doi.org/10.3390/cancers16152630, doi:10.3390/cancers16152630. This article has 3 citations and is from a peer-reviewed journal.
16. (singh2018explorationofthe pages 2-3): Pankaj Kumar Singh, Aanchal Kashyap, and O. Silakari. Exploration of the therapeutic aspects of lck: a kinase target in inflammatory mediated pathological conditions. Biomedicine & Pharmacotherapy, 108:1565-1571, Dec 2018. URL: https://doi.org/10.1016/j.biopha.2018.10.002, doi:10.1016/j.biopha.2018.10.002. This article has 69 citations.
17. (singh2018explorationofthe pages 3-5): Pankaj Kumar Singh, Aanchal Kashyap, and O. Silakari. Exploration of the therapeutic aspects of lck: a kinase target in inflammatory mediated pathological conditions. Biomedicine & Pharmacotherapy, 108:1565-1571, Dec 2018. URL: https://doi.org/10.1016/j.biopha.2018.10.002, doi:10.1016/j.biopha.2018.10.002. This article has 69 citations.
18. (singh2018explorationofthe pages 5-6): Pankaj Kumar Singh, Aanchal Kashyap, and O. Silakari. Exploration of the therapeutic aspects of lck: a kinase target in inflammatory mediated pathological conditions. Biomedicine & Pharmacotherapy, 108:1565-1571, Dec 2018. URL: https://doi.org/10.1016/j.biopha.2018.10.002, doi:10.1016/j.biopha.2018.10.002. This article has 69 citations.
19. (talab2013lckisan pages 1-2): Fatima Talab, John C. Allen, Victoria Thompson, Ke Lin, and Joseph R. Slupsky. Lck is an important mediator of b-cell receptor signaling in chronic lymphocytic leukemia cells. Molecular Cancer Research, 11:541-554, May 2013. URL: https://doi.org/10.1158/1541-7786.mcr-12-0415-t, doi:10.1158/1541-7786.mcr-12-0415-t. This article has 84 citations and is from a peer-reviewed journal.
20. (talab2013lckisan pages 14-15): Fatima Talab, John C. Allen, Victoria Thompson, Ke Lin, and Joseph R. Slupsky. Lck is an important mediator of b-cell receptor signaling in chronic lymphocytic leukemia cells. Molecular Cancer Research, 11:541-554, May 2013. URL: https://doi.org/10.1158/1541-7786.mcr-12-0415-t, doi:10.1158/1541-7786.mcr-12-0415-t. This article has 84 citations and is from a peer-reviewed journal.
21. (till2017lckisa pages 1-2): Kathleen J. Till, John C. Allen, Fatima Talab, Ke Lin, David Allsup, Lynn Cawkwell, Alison Bentley, Ingo Ringshausen, Andrew D. Duckworth, Andrew R. Pettitt, Nagesh Kalakonda, and Joseph R. Slupsky. Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome. Scientific Reports, Dec 2017. URL: https://doi.org/10.1038/s41598-017-17021-w, doi:10.1038/s41598-017-17021-w. This article has 18 citations and is from a poor quality or predatory journal.
22. (zhu1999structuralanalysisof pages 1-2): Xiaotian Zhu, Joseph L Kim, John R Newcomb, Paul E Rose, David R Stover, Leticia M Toledo, Huilin Zhao, and Kurt A Morgenstern. Structural analysis of the lymphocyte-specific kinase lck in complex with non-selective and src family selective kinase inhibitors. Structure, 7:651-661, Jun 1999. URL: https://doi.org/10.1016/s0969-2126(99)80086-0, doi:10.1016/s0969-2126(99)80086-0. This article has 334 citations and is from a domain leading peer-reviewed journal.
23. (zhu1999structuralanalysisof pages 11-11): Xiaotian Zhu, Joseph L Kim, John R Newcomb, Paul E Rose, David R Stover, Leticia M Toledo, Huilin Zhao, and Kurt A Morgenstern. Structural analysis of the lymphocyte-specific kinase lck in complex with non-selective and src family selective kinase inhibitors. Structure, 7:651-661, Jun 1999. URL: https://doi.org/10.1016/s0969-2126(99)80086-0, doi:10.1016/s0969-2126(99)80086-0. This article has 334 citations and is from a domain leading peer-reviewed journal.
24. (zhu1999structuralanalysisof pages 7-8): Xiaotian Zhu, Joseph L Kim, John R Newcomb, Paul E Rose, David R Stover, Leticia M Toledo, Huilin Zhao, and Kurt A Morgenstern. Structural analysis of the lymphocyte-specific kinase lck in complex with non-selective and src family selective kinase inhibitors. Structure, 7:651-661, Jun 1999. URL: https://doi.org/10.1016/s0969-2126(99)80086-0, doi:10.1016/s0969-2126(99)80086-0. This article has 334 citations and is from a domain leading peer-reviewed journal.
25. (zhu1999structuralanalysisof pages 8-9): Xiaotian Zhu, Joseph L Kim, John R Newcomb, Paul E Rose, David R Stover, Leticia M Toledo, Huilin Zhao, and Kurt A Morgenstern. Structural analysis of the lymphocyte-specific kinase lck in complex with non-selective and src family selective kinase inhibitors. Structure, 7:651-661, Jun 1999. URL: https://doi.org/10.1016/s0969-2126(99)80086-0, doi:10.1016/s0969-2126(99)80086-0. This article has 334 citations and is from a domain leading peer-reviewed journal.
26. (borowicz2020regulationoft pages 20-24): P Borowicz. Regulation of t cell activation by two conserved phosphotyrosines in lck and its adapter protein tsad. Unknown journal, 2020.
27. (borowicz2020regulationoft pages 63-66): P Borowicz. Regulation of t cell activation by two conserved phosphotyrosines in lck and its adapter protein tsad. Unknown journal, 2020.
28. (borowicz2020regulationoft pages 73-75): P Borowicz. Regulation of t cell activation by two conserved phosphotyrosines in lck and its adapter protein tsad. Unknown journal, 2020.
29. (borowicz2020regulationoft pages 77-79): P Borowicz. Regulation of t cell activation by two conserved phosphotyrosines in lck and its adapter protein tsad. Unknown journal, 2020.
30. (corwin2016decipheringhumancytoplasmic pages 13-16): T Corwin. Deciphering human cytoplasmic protein tyrosine kinase phosphorylation specificity in yeast. Unknown journal, 2016.
31. (korademirnics2000srckinasemediatedsignaling pages 1-2): Željka Korade-Mirnics and Seth J Corey. Src kinase-mediated signaling in leukocytes. Journal of Leukocyte Biology, 68:603-613, Nov 2000. URL: https://doi.org/10.1189/jlb.68.5.603, doi:10.1189/jlb.68.5.603. This article has 160 citations and is from a peer-reviewed journal.